Stevanato Group, a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, has introduced Deora, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programmes.
Deora is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject.
This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations.
The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL.
The device architecture provides flexibility across multiple fixed-dose configurations while minimising the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialisation and scalable manufacturing.
Deora leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialisation. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners.
Together, these characteristics position Deora as a platform intended to support partners as they advance early development programmes and prepare for future scale-up.
